An Update in Management of Noncutaneous T-Cell Lymphomas

Abstract EN

T-cell lymphoma is a heterogeneous group of diseases.

Except for ALK positive anaplastic large cell lymphoma, T-cell lymphoma responds to conventional chemotherapy unfavourably, and most patients carry poor prognosis.

In recent years, efforts have been made to improve the outcome of T-cell lymphoma patients.

Novel agents, high-dose therapy, and allogeneic stem cell transplantation are studied, and various results are reported in literature.

This paper looks into the prognostication and treatment approach of different entities of noncutaneous T-cell lymphoma and would focus on the latest updates in its management.